Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Iamarangerboy who wrote (10082)	5/19/2007 1:14:23 AM
From: John Metcalf	Read Replies (1) \| Respond to of 10280

Yep, the market over-reacted. At the mid-points, and assuming the worst case, the decrease is Xop reimbursement to $.71-$.81 from $,92-1.54, at 15% of sales to Medicare/caid patients would be 2.8% to 4.1% of sales. Sales growth, all products, should overcome that decrease. Jon is probably right that the decrease in EP/S is proportionately larger. I sold puts and bought calls on SEPR today, at the $50 strike for January expiration. Woe is me!